Cetuximab

A combination of palbociclib and cetuximab demonstrated substantial antitumor activity among patients with platinum- or cetuximab-resistant HPV-unrelated head and neck squamous cell carcinoma, according to results of a multigroup phase 2 trial published in The Lancet Oncology.

Consensus molecular subtype classification demonstrated potential clinical utility as an independent prognostic factor for patients with metastatic colorectal cancer who receive first-line therapy, according to results of a prospective phase 3 trial published in Journal of Clinical Oncology.